Soligenix data-enriched by China mucositis deal with SciClone
This article was originally published in Scrip
Executive Summary
As part of a strategy to focus solely on developing its Chinese commercial business, the US firm SciClone Pharmaceuticals has signed its third licensing deal in the past three months, this time acquiring rights in China to Soligenix' innate defense regulator for oral mucositis SGX942.
You may also be interested in...
Asia Deal Watch: Busy Eikon Partners With Impact On Selective PARP1 Inhibitors
Yuhan and J INTS BIO and Betta and C4 sign deals centered on lung cancer candidates. Viatris’s Japanese affiliate gets in-country rights to InDex’s Phase III ulcerative colitis candidate.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: a preview of ASCO; Roche CEO on new opportunities; Sanofi sees success in MS; Phase II lupus win for AbbVie; and a Chinese product case study in psoriasis.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.